Home LiteratureArticle Details
PMID: 19393083 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.

Breast cancer research : BCR ·Vol. 11 ·No. 2 ·2009-00-00 ·Pages R21

Reed JR, Leon RP, Hall MK, Schwertfeger KL

Abstract

Inflammation within the tumour microenvironment correlates with increased invasiveness and poor prognosis in many types of cancer, including breast cancer. We have previously demonstrated that activation of a mouse mammary tumour virus (MMTV)-driven inducible fibroblast growth factor receptor 1 (iFGFR1) transgene in mammary epithelial cells results in an inflammatory response characterised by induction of inflammatory genes in the mammary gland. Specifically, we have observed increased levels of IL-1beta expression in the mammary gland following activation of iFGFR1 and have used the iFGFR1 model to elucidate the function of IL-1beta in promoting iFGFR1-induced mammary lesions. To determine the functional consequences of IL-1beta induction during FGFR1-induced mammary tumourigenesis, the effects of IL-1beta inhibition on the formation of epithelial hyperplasias were examined using the MMTV-iFGFR1 transgenic mouse model. Further studies used a combination of the HC-11 mammary epithelial cell line that stably expresses iFGFR1 and the MMTV-iFGFR1 transgenic mice to further define the mechanisms of IL-1beta function. Inhibition of IL-1beta activity in vivo resulted in reduced iFGFR1-induced epithelial proliferation and formation of hyperplastic structures. Further studies demonstrated that treatment of mammary epithelial cells with IL-1beta-induced expression of cyclooxygenase (Cox)-2 both in vitro and in vivo. Finally, inhibition of Cox-2 prior to activation of iFGFR1 in the transgenic mice also resulted in decreased iFGFR1-induced formation of hyperplastic structures. The results from these studies indicate that targeting the inflammatory cytokine IL-1beta partially inhibits iFGFR1-induced formation of early-stage mammary lesions, in part through induction of Cox-2. These findings demonstrate that activation of a growth factor receptor in mammary epithelial cells results in increased expression of inflammatory mediators, which cooperate to promote the initiation of hyperplastic lesions in the mammary gland.

MeSH Terms
Animals Blotting, Western Cell Movement Cyclooxygenase 2/biosynthesis Enzyme-Linked Immunosorbent Assay Female Hyperplasia Immunoenzyme Techniques Interleukin-1beta/physiology Mammary Neoplasms, Experimental/enzymology,pathology Mice Mice, Transgenic NF-kappa B/genetics,metabolism Phenotype RNA, Messenger/genetics,metabolism Receptor, Fibroblast Growth Factor, Type 1/physiology Reverse Transcriptase Polymerase Chain Reaction
Chemicals
Interleukin-1beta NF-kappa B RNA, Messenger Ptgs2 protein, mouse Cyclooxygenase 2 Fgfr1 protein, mouse Receptor, Fibroblast Growth Factor, Type 1
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Reed Johanna R
Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA.
Leon Ronald P
Hall Majken K
Schwertfeger Kathryn L
References (40)
40 references, click to expand
  1. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development.
    Development. 2007 Aug;134(15):2739-50 PMID: 17611223
  2. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
    Breast Cancer Res. 2007;9(2):R23 PMID: 17397528
  3. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.
    BMC Cancer. 2003 Oct 31;3:28 PMID: 14588079
  4. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.
    J Transl Med. 2006 Nov 10;4:48 PMID: 17096856
  5. SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
    Breast Cancer Res Treat. 2005 Jan;89(1):5-14 PMID: 15666191
  6. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  7. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
    Methods. 2001 Dec;25(4):402-8 PMID: 11846609
  8. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
    Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91 PMID: 14693742
  9. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Cancer Cell. 2006 Dec;10(6):529-41 PMID: 17157792
  10. Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line.
    EMBO J. 1988 Jul;7(7):2089-95 PMID: 3416834
  11. Cyclooxygenase-2 expression during immortalization and breast cancer progression.
    Cancer Res. 2008 Jan 15;68(2):467-75 PMID: 18199541
  12. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression.
    Oncol Rep. 1999 Jan-Feb;6(1):65-70 PMID: 9864403
  13. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
    J Surg Res. 2008 Jun 15;147(2):240-6 PMID: 18498876
  14. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.
    JAMA. 2004 May 26;291(20):2433-40 PMID: 15161893
  15. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.
    Cancer Res. 2003 Sep 15;63(18):6096-101 PMID: 14522941
  16. The IL-1 family and inflammatory diseases.
    Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S1-13 PMID: 14989423
  17. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?
    Immunol Rev. 2008 Apr;222:222-41 PMID: 18364005
  18. Reduced expression of cyclooxygenase-2 in primary breast cancer.
    J Natl Cancer Inst. 2008 Jul 16;100(14):1042-3 PMID: 18612134
  19. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
    J Clin Oncol. 2008 Mar 10;26(8):1253-9 PMID: 18323548
  20. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression.
    Int J Oncol. 2003 Aug;23(2):269-84 PMID: 12851675
  21. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
    Biochem Pharmacol. 2004 Sep 15;68(6):1089-100 PMID: 15313405
  22. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
    J Biol Chem. 2002 May 24;277(21):18649-57 PMID: 11901151
  23. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Immunol Rev. 2008 Apr;222:155-61 PMID: 18364000
  24. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland.
    J Cell Biol. 2002 May 13;157(4):703-14 PMID: 12011115
  25. NSAIDs and breast cancer recurrence in a prospective cohort study.
    Cancer Causes Control. 2007 Aug;18(6):613-20 PMID: 17404892
  26. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
    Cancer Res. 2002 Mar 15;62(6):1676-81 PMID: 11912139
  27. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.
    Breast Cancer Res. 2007;9(4):210 PMID: 17640394
  28. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD.
    Int J Cancer. 2007 Jul 1;121(1):211-15 PMID: 17330846
  29. Breast cancer and NSAID use: a meta-analysis.
    Br J Cancer. 2001 May 4;84(9):1188-92 PMID: 11336469
  30. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model.
    J Cell Biol. 2005 Nov 21;171(4):663-73 PMID: 16301332
  31. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.
    Genes Dev. 2006 Sep 15;20(18):2527-38 PMID: 16980582
  32. Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction.
    Methods Enzymol. 2002;345:556-69 PMID: 11665639
  33. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
    Breast Cancer Res. 2007;9(4):212 PMID: 17705880
  34. COX-2 overexpression increases motility and invasion of breast cancer cells.
    Int J Oncol. 2005 May;26(5):1393-9 PMID: 15809733
  35. The role of C/EBPbeta in mammary gland development and breast cancer.
    J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):191-204 PMID: 14635794
  36. COX inhibitors and breast cancer.
    Br J Cancer. 2006 Feb 13;94(3):346-50 PMID: 16421592
  37. A critical role for the inflammatory response in a mouse model of preneoplastic progression.
    Cancer Res. 2006 Jun 1;66(11):5676-85 PMID: 16740705
  38. Cytokines in breast cancer.
    Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37 PMID: 16931107
  39. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition.
    Mol Endocrinol. 2007 Apr;21(4):987-1000 PMID: 17284663
  40. Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells.
    Mol Cancer Res. 2007 Aug;5(8):847-61 PMID: 17670913
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2009-00-00
Epub
2009-00-24
Pages
R21
Language
English
Region
England
NLM ID
100927353
PMCID
PMC2688950
Subset
IM
Grants
NCRR NIH HHS · S10 RR016851 · United States
NCI NIH HHS · T32 CA009138 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com